RightFit
RecruitingNot applicable

Artificial Intelligence (AI)-Enhanced Pretreatment Peer-review Process to Improve Patient Safety in Radiation Oncology

Development and Assessment of Artificial Intelligence (AI)-Enhanced Pretreatment Peer-review Process to Improve Patient Safety in Radiation Oncology

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years and older
Sex
All sexes
Healthy volunteers
Accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

In plain language

This study tests whether artificial intelligence (AI) tools can help care teams find possible mistakes in radiation treatment plans before care starts. It is for adult staff who attend plan-review meetings and adults treated with radiation for prostate cancer at participating clinics. Patients do not receive a study treatment.

This prospective study will test artificial intelligence (AI) and machine learning (ML) decision support tools. This tool is designed to help doctors, physicists and other staff during pre-treatment peer review, a step where treatment plans are checked before a patient begins care. The system highlights summaries showing how different providers may vary in their treatment planning (provider-variability summaries) and points out the best signals or warning signs to look for (optimal cues). By drawing attention to these patterns and cues, the tool aims to help reviewers spot possible treatment-planning mistakes earlier, reduce the chance of errors, and improve overall patient safety.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Who can join

  • Staff: Must be age 18 or older.
  • Staff: Must attend meetings to review treatment plans at participating clinics.
  • Patients: Must be age 18 or older.
  • Patients: Must have a prostate cancer radiation treatment case at a participating clinic.

Who can't join

  • Staff: Cannot or do not want to follow study steps.
  • Sites: Cannot use the study process or provide the required results.
  • Patients and staff: Have dementia, confused thinking, a mental health condition, or another health condition that prevents them from understanding or giving consent to join.

Simplified for readability. The official criteria below are what the study team uses.

Official eligibility criteria

In order to participate in this study a subject must meet all of the eligibility criteria outlined below. Inclusion Criteria: Providers only * ≥18 years * Peer-review attendees at participating clinics Patients only * ≥18 years * All patients with prostate cancer radiation therapy cases treated at participating sites (no intervention delivered to patients) Exclusion Criteria: Providers only • Providers unwilling/unable to comply with study procedures; sites unable to implement the workflow or provide required outcomes. Patients and Providers • Has dementia, altered mental status, or any psychiatric or co-morbid condition prohibiting the understanding or rendering of informed consent

Study sites (1)

NC